Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0000950170-25-018909
Filing Date
2025-02-12
Accepted
2025-02-12 16:30:06
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 16706
  Complete submission text file 0000950170-25-018909.txt   18614
Mailing Address 500 RUTHERFORD AVENUE 3RD FLOOR CHARLESTOWN MA 02129
Business Address 500 RUTHERFORD AVENUE 3RD FLOOR CHARLESTOWN MA 02129 617-337-4680
Solid Biosciences Inc. (Subject) CIK: 0001707502 (see all company filings)

EIN.: 900943402 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-90280 | Film No.: 25615279
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address THE INVUS GROUP, LLC 750 LEXINGTON AVENUE, 30TH FLOOR NEW YORK NY 10022
Business Address THE INVUS GROUP, LLC 750 LEXINGTON AVENUE, 30TH FLOOR NEW YORK NY 10022 212-371-1717
Invus Global Management, LLC (Filed by) CIK: 0002005369 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A